Home / Research library / Pancragen
Pancragen: molecular data, studies & sources
Pancragen is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C26H36N6O9
- Molecular weight (MW)
- 576.6 g/mol
- PubChem compound ID
- 68452877
- Record title
- H-Lys-Glu-Asp-Trp-OH
This source structure is Lys-Glu-Asp-Trp (KEDW), the sequence identified as Pancragen in PMID 22808515. The formula describes this specific unmodified peptide record, not a vendor batch.
Source: PubChem CID 68452877 · retrieved 2026-09-21 · Identity cross-reference

Chemical identifiers and source data
- IUPAC name
- (4S)-5-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-1-oxopropan-2-yl]amino]-4-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoic acid
- InChIKey
- PIGJHNNSOMRLST-LEAZDLGRSA-N
- SMILES
- C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N
Identifiers & sequence
- PubChem CID
- 68452877
- InChIKey
- PIGJHNNSOMRLST-LEAZDLGRSA-N
Peptide sequence · 4 residues (one-letter code; X marks a residue without a one-letter code)
KEDW
Condensed notation with terminal groups and non-standard residues
H-Lys-Glu-Asp-Trp-OH
Source: PubChem Biologic Line Notation. A reference sequence for the record, not an analysis of a supplied batch.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 576.2544 Da |
|---|---|
| Heavy atoms | 41 |
| Hydrogen-bond donors | 9 |
| Hydrogen-bond acceptors | 8 |
| Rotatable bonds | 18 |
| Topological polar surface area | 267.0 Ų |
| Calculated logP (Crippen) | -0.95 |
| Rings | 2 |
| Stereocenters | 4 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Pancragen as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.
Registry check 2026-10-01 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Pancragen, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Research publication · design requires review
Effects of pancragen on the differentiation of pancreatic cells during their ageing.
Khavinson VKh, Durnova AO, Polyakova VO et al. · Bulletin of experimental biology and medicine · 2013
PMID 23486591 · DOI: 10.1007/s10517-013-1987-6
- Preclinical / laboratory research
[Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys].
Goncharova ND, Ivanova LG, Oganyan TE et al. · Advances in gerontology = Uspekhi gerontologii · 2015
PMID 28509500
- Preclinical / laboratory research
Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus.
Khavinson VKh, Gavrisheva NA, Malinin VV et al. · Bulletin of experimental biology and medicine · 2007
PMID 18642713 · DOI: 10.1007/s10517-007-0377-3
- Preclinical / laboratory research
Peptides tissue-specifically stimulate cell differentiation during their aging.
Khavinson VKh, Linkova NS, Polyakova VO et al. · Bulletin of experimental biology and medicine · 2012
Experiments in cultured human-derived cells. Human cell culture is not a clinical trial in people.
PMID 22808515 · DOI: 10.1007/s10517-012-1664-1
- Preclinical / laboratory research
[The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats].
Zakutskiĭ AN, Chalisova NI, Ryzhak GA et al. · Advances in gerontology = Uspekhi gerontologii · 2006
Organotypic tissue cultures from young and aged rats. Tissue-culture responses do not demonstrate patient benefit.
PMID 17152728
Pancragen supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Pancragen for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Cenexa LabsUSD | 20mg Vial1 recorded offers | 20mg Vial · $64.99Checked Oct 13, 2026Supplier listing, Pancragen 20mg Vial, Cenexa Labs, opens in a new tab |
Reference sources & further reading
- PubChem compound record 68452877 — chemical identity and structure.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Bronchogen
C18H30N4O9
446.5 g/mol · PubChem CID 11690869
6 selected publications · 0 human intervention studies
Cardiogen
Molecular identity needs further verification
1 selected publication · 0 human intervention studies
Cartalax
C12H19N3O8
333.29 g/mol · PubChem CID 87815447
0 selected publications · 0 human intervention studies
Chonluten
C11H17N3O8
319.27 g/mol · PubChem CID 194641
1 selected publication · 0 human intervention studies
Cortagen
C17H26N4O9
430.4 g/mol · PubChem CID 18439621
5 selected publications · 0 human intervention studies
Epithalon
C14H22N4O9
390.35 g/mol · PubChem CID 219042
4 selected publications · 1 human intervention study